APA (7th ed.) Citation

Henderson, M. A., Burmeister, B. H., Ainslie, J., Fisher, R., Di Iulio, J., Smithers, B. M., . . . Thompson, J. F. (2015). Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncology, 16(9), 1049. https://doi.org/10.1016/S1470-2045(15)00187-4

Chicago Style (17th ed.) Citation

Henderson, Michael A., et al. "Adjuvant Lymph-node Field Radiotherapy Versus Observation Only in Patients with Melanoma at High Risk of Further Lymph-node Field Relapse After Lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year Follow-up of a Phase 3, Randomised Controlled Trial." Lancet Oncology 16, no. 9 (2015): 1049. https://doi.org/10.1016/S1470-2045(15)00187-4.

MLA (9th ed.) Citation

Henderson, Michael A., et al. "Adjuvant Lymph-node Field Radiotherapy Versus Observation Only in Patients with Melanoma at High Risk of Further Lymph-node Field Relapse After Lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year Follow-up of a Phase 3, Randomised Controlled Trial." Lancet Oncology, vol. 16, no. 9, 2015, p. 1049, https://doi.org/10.1016/S1470-2045(15)00187-4.